로딩 중…
지수 로딩 중…
Hyundai Bioscience
048410· KOSDAQ· Consumer Staples· Household & Personal Products
₩8,820-4.13%
2026-06-19
Price Chart
Hyundai Bioscience+94.70%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 851.18B KRW |
| Revenue | 3.13B KRW |
| Net Income | -3.91B KRW |
| Total Assets | 129.10B KRW |
| Net Assets | 111.98B KRW |
| Employees | 55 |
| Value | |
| P/B | 7.60x |
| P/S | 271.66x |
| FCF Yield | -2.05% |
| Profitability | |
| ROE | -3.49% |
| ROA | -3.03% |
| Op. Margin | -591.83% |
| Revenue Growth | -54.19% |
| Financial Health | |
| Debt Ratio | 115.29% |
| Total Debt | 14.68B KRW |
| FCF | -17.47B KRW |
| Cash | 8.13B KRW |
| Current Ratio | 2.40x |
| Performance | |
| 1Y Return | 94.70% |
| 1M Return | -16.16% |
| From 52W High | -58.98% |
| 1Y MDD | -58.20% |
| Trading | |
| Volume | 1,030,905 shares |
| Foreign Own. | 6.04% |
| Per Share | |
| EPS | -222 KRW |
| BPS | 1,160 KRW |
Company Info
Spun off from Hyundai Electronics in 2000, this bio pharmaceutical and cosmeceutical company was listed on KOSDAQ in 2002 and renamed Hyundai Bioscience in 2018. It is developing the broad-spectrum antiviral treatment CP-COV03 and anticancer drugs Polytaxel and Penicillium, while expanding its domestic and international markets with high-functional cosmetics Vitabrid C12 (exported to Japan) and Dr.BRID C. The company is securing new drug development pipelines in cooperation with C&Pharm and pursuing commercialization of clinical results through exchanges with international organizations. Hyundai Bio is headquartered in Gimcheon-si, Gyeongsangbuk-do.